Skip to content

Oxygen Portable Concentrator During Exercises in Patients With COPD

Comparing Effectiveness of Oxygen Supplementation From a Portable Concentrator and a Liquid Oxygen Source During Walking Test in COPD Patients With Respiratory Failure

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00875719
Enrollment
19
Registered
2009-04-03
Start date
2009-02-28
Completion date
2011-02-28
Last updated
2011-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPD patients with respiratory failure

Brief summary

The purpose of this study is to compare differences in oxygen delivery between portable oxygen concentrators (POCs) and liquid oxygen (LOs) portable units, pose a question if POCs are equally effective as LOs in reducing exercise-induced hypoxaemia. DESIGN: Randomized, single-blind clinical trial.

Detailed description

Our primary objective is to compare at rest and during exercise the evolution of oxygen saturation and dyspnea during 6 minutes walking test in patients with COPD receiving oxygen supplementation either with portable concentrators or liquid oxygen in a random order.

Interventions

DEVICEOxygen concentrators versus constant flow axygen

Each patient performed 2 walking tests, and received oxygen supplementation from a portable concentrator or a liquid oxygen source, in a random order.

comparison walk distance and saturation with continuous oxygen compared to intermittent oxygen

Sponsors

Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* COPD with respiratory failure and indication for oxygen supplementation at rest and/or during exercice.

Exclusion criteria

* Evolutive heart disease. * Unability to understand or realize the tests. * Acute exacerbation during the last month.

Design outcomes

Primary

MeasureTime frame
Oxygen SaturationOne day

Secondary

MeasureTime frame
Walking DistanceOne day

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026